Personalized medicine for the management of benign prostatic hyperplasia - Wikidata - awgldk - TriplyDB

Personalized medicine for the management of benign prostatic hyperplasia

Personalized medicine for the management of benign prostatic hyperplasia

http://www.wikidata.org/entity/Q34084593

about

The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression Urinary proteomics and metabolomics studies to monitor bladder health and urological diseases Recent advances in treatment for Benign Prostatic Hyperplasia Drug therapy of overactive bladder--what is coming next?Mechanisms of hemorrhagic cystitis.Aberrant Transforming Growth Factor-β Activation Recruits Mesenchymal Stem Cells During Prostatic Hyperplasia.DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate Inflammation and pyroptosis mediate muscle expansion in an interleukin-1β (IL-1β)-dependent manner DNA methylation as a dynamic regulator of development and disease processes: spotlight on the prostate A Systematic Review of Prostatic Artery Embolization in the Treatment of Symptomatic Benign Prostatic Hyperplasia.Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia.CD8+ T cells promote proliferation of benign prostatic hyperplasia epithelial cells under low androgen level via modulation of CCL5/STAT5/CCND1 signaling pathway.Molecular classification of benign prostatic hyperplasia: A gene expression profiling study in a rat model.Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?Molecular pathogenesis of human prostate basal cell hyperplasia.Widespread telomere instability in prostatic lesions.DNMT1 regulates IL-6- and TGF-β1-induced epithelial mesenchymal transition in prostate epithelial cells.Precision Medicine and Men's Health.Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2.Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia.Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.Prostatic Artery Embolization After Failed Urological Interventions for Benign Prostatic Obstruction: A Case Series of Three Patients.Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target.

P2860

Q24564068-A84ACA35-1255-43F0-9A59-510B51D542C6 Q26752864-44D73508-C84E-46F5-85CC-4D489D3F1861 Q26766218-60B1E3CF-57EC-4F08-8723-21B5A3DE1270 Q26780197-B6DBCC51-9983-4A14-B5C2-0CDD787C6DC5 Q27686784-5C409EA5-991D-4B6C-B8F5-1F38183BF451 Q33722426-1FCECCF4-AA1D-4F0C-A555-E77687FECBCE Q35143766-C0C5D1B5-0ACC-4EA3-A0A5-415BD8BD3BCA Q35173027-73201898-E293-4F3C-8DE6-248891BCB510 Q35847749-59AC428D-CE0F-4D0C-8F6B-649FEE6D18A7 Q36235243-6DB34A53-017D-4622-97B8-5B4BD62135DD Q36602183-8028B7E8-B343-4C14-9633-03231ABD69E8 Q37652222-CBB115B3-6D58-4AAA-AA77-1D8A36019309 Q38447424-94D25E9D-1D42-4335-B28D-46A0DB054C93 Q38571198-B183FCDE-E875-4696-A598-EBFFBE2D0F12 Q38631071-FB5F6EEE-7896-4232-A04A-321261D529DB Q38881676-C18BAF11-10B6-413B-AE8F-A648DE06C67A Q42264513-970D5CC5-B4E4-41F3-8363-6EAF50F58E48 Q47151829-0B866295-8EA7-4679-B5F8-28D4F8E0F719 Q47756626-D0BDC86A-AEDE-4886-8C76-E34C1680FAC0 Q49039304-C27E562A-A85B-4BE5-90F0-349244104088 Q49971559-F88567F5-0CD3-4235-85D2-1DFFAE2E4B72 Q52983653-5009F141-AF79-422A-9BA6-6E3320FD6690 Q55515702-1EB43193-8915-411A-BF3F-99C8F4EA5A9B

P2860

Personalized medicine for the management of benign prostatic hyperplasia

http://www.wikidata.org/entity/Q34084593

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Personalized medicine for the management of benign prostatic hyperplasia

@ast

Personalized medicine for the management of benign prostatic hyperplasia

@en

Personalized medicine for the management of benign prostatic hyperplasia

@nl

type

label

Personalized medicine for the management of benign prostatic hyperplasia

@ast

Personalized medicine for the management of benign prostatic hyperplasia

@en

Personalized medicine for the management of benign prostatic hyperplasia

@nl

prefLabel

Personalized medicine for the management of benign prostatic hyperplasia

@ast

Personalized medicine for the management of benign prostatic hyperplasia

@en

Personalized medicine for the management of benign prostatic hyperplasia

@nl

P1433

Q34084593-EDD4E8A7-AB47-462C-9DB6-EE594B7A6990

P1476

Q34084593-7E0FC09E-438D-489A-AC05-E9F0ABE2D302

P2093

Q34084593-B8CFA059-04D8-4A15-92CB-AF0C2A320F38

Q34084593-BEC4CBB3-2EE0-4505-BEA8-2598469F61C9

Q34084593-E4355005-4893-4E67-924F-FABD614F7E83

Q34084593-F9B28532-B0C1-47A4-9F6A-3F897D4AC4FA

P2860

Q34084593-00696869-4A8D-4A7B-8C40-F673E57C31A6

Q34084593-089E4068-76E8-4E30-9609-0C52224F5790

Q34084593-1A8C58EF-B37C-4F01-9910-EC38DD8603B8

Q34084593-1F590C31-C23B-47CB-BAE5-2B1040BAD72C

Q34084593-1FE9AB4F-4161-433B-AF66-3F0F23A4D4F5

Q34084593-235AA2B2-FF9E-445C-BC00-87E87EC4E453

Q34084593-2696F5BD-3E9A-49E6-B138-43FA0DE109BB

Q34084593-2EF05E2E-F9D7-4ED0-8008-A134A54FB820

Q34084593-3DE8B6D1-F6E7-41F6-9CE2-03C310948F9A

Q34084593-3EFC7210-38AD-40D0-B8C0-287573E12793

P304

Q34084593-866BC794-44BF-4069-B909-5A80CA3B0B29

P31

Q34084593-79CDBC22-CE13-48DB-8E54-910260D267EA

P356

Q34084593-073FA0E2-6727-4ED0-B2CB-753330F5F1AB

P407

Q34084593-A3F4A0AF-BDEE-4890-8269-3047474ED57B

P433

Q34084593-A1B96C0B-590B-456F-BEEC-9406428D1A61

P478

Q34084593-8C4972E5-589D-4BA1-8FAD-D4BD494B1132

P577

Q34084593-0FC996CF-C8FA-484A-86D7-DE390C735D10

P698

Q34084593-A9C0129F-0C80-4423-94DA-7874DF05688F

P932

Q34084593-37F70533-FBEA-469E-A0E5-F9530B8D98A1

P356

J.JURO.2014.01.114

P1433

The Journal of Urology

P1476

Personalized medicine for the management of benign prostatic hyperplasia

@en

P2093

Alexander G Otsetov

http://www.w3.org/2001/XMLSchema#string

Aria F Olumi

http://www.w3.org/2001/XMLSchema#string

Rongbin Ge

http://www.w3.org/2001/XMLSchema#string

Seth K Bechis

http://www.w3.org/2001/XMLSchema#string

P2860

Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis

A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium.

Finasteride reduces the risk of incident clinical benign prostatic hyperplasia

Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers--results from BPC3.

Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays.

A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

The functional role of reactive stroma in benign prostatic hyperplasia.

The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.

P304

16-23

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JURO.2014.01.114

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

192

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24582540

http://www.w3.org/2001/XMLSchema#string

P932

4143483

http://www.w3.org/2001/XMLSchema#string